Curcumin Micelles Entrapped in Eudragit S-100 Matrix: a Synergistic Strategy for Enhanced Oral Delivery

Figures & data

Figure 1. Powder yield (%) of curcumin micelle-EUD dry powder formulations prepared at different molar ratios of curcumin:poloxamer407:eudragit S100.

(F1) 1:0.6: 1.3; (F2) 1:0.7:1.4; (F3) 1:0.8:1.5 and (F4) 1:0.9:1.6.

Figure 2. Scanning electron microscopy images of curcumin micelle-eudragit s-100 dry powder formulations prepared at different molar ratios of curcumin:poloxamer 407:eudragit S100.

(F1) 1:0.6: 1.3; (F2) 1:0.7:1.4; (F3) 1:0.8:1.5 and (F4) 1:0.9:1.6.

Figure 3. Differential thermal analysis thermograms of CUR, EUD, POL.

CUR: Curcumin; EUD: eudragit s-100; POL: Poloxamer 407.

Figure 4. Differential thermal analysis thermograms of curcumin micelle-eudragit s-100 dry powder formulations prepared at different molar ratios of curcumin:poloxamer 407:eudragit S100.

(F1) 1:0.6: 1.3; (F2) 1:0.7:1.4; (F3) 1:0.8:1.5 and (F4) 1:0.9:1.6. Their PM was prepared using the same ratio as F1.

PM: Physical mixture.

Figure 5. Powder x-ray diffractograms of CUR, EUD, POL.

CUR: Curcumin; EUD: eudragit s-100; POL: Poloxamer 407.

Figure 6. Powder x-ray diffractograms of curcumin micelle-eudragit s-100 dry powder formulations prepared at different molar ratios of curcumin:poloxamer407:eudragit S100 and their physical mixture.

(F1) 1:0.6:1.3; (F2) 1:0.7:1.4; (F3) 1:0.8:1.5 and (F4) 1:0.9:1.6. Their PM was prepared using the same ratio as F1.

PM: Physical mixture.

Figure 7. In vitro curcumin release (%) from curcumin micelle-eudragit s-100 dry powder formulations prepared in phosphate-buffered saline (pH 6.8) at 37°C at different molar ratios of curcumin:poloxamer 407:eudragit S100.

(F1) 1:0.6:1.3; (F2) 1:0.7:1.4; (F3) 1:0.8:1.5 and (F4) 1:0.9:1.6.